--(BUSINESS WIRE)--HDT Bio Corp. is bringing immunotherapies to people around the world. With a focus on RNA, formulation, and adjuvant technologies, HDT Bio is developing biotherapeutics for oncology and infectious disease applications. HDT Bio simultaneously works to integrate therapeutic approaches for first-in-class medicines while building on decades of development experience with well-established pharmaceutical ingredients. The resulting products are poised to significantly affect the lives of millions of people worldwide and to provide access to lifesaving therapies for underserved populations. One of the company’s core technologies, RNA/LION, combines formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses for therapy or vaccination.
Company: |
HDT Bio Corp. |
|
|
|
|
Headquarters Address: |
1616 EASTLAKE AVE E |
|
|
SUITE 280 |
|
|
SEATTLE, WA 98102 |
|
|
|
|
Main Telephone: |
425-241-4152 |
|
|
|
|
Website: |
||
|
|
|
Type of Organization: |
Private |
|
|
|
|
Industry: |
Biotechnology |
|
|
|
|
Key Executives: |
COO: Christopher Pirie |
|
|
CEO: Steven Reed |
|
|
CSO: Darrick Carter |
|
|
|
|
COO |
|
|
Contact: |
Christopher Pirie |
|
Phone: |
425-241-4152 |
|
Email: |
